Page last updated: 2024-08-23

diltiazem and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

diltiazem has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burbury, KL; Dobie, G; Grigg, AP; Hamadi, A; Jackson, DE; Kwa, FA; Schwarer, AP	1

Other Studies

1 other study(ies) available for diltiazem and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. Thrombosis and haemostasis, 2019, Volume: 119, Issue:7 Topics: Animals; Antineoplastic Agents; Blood Platelets; Cells, Cultured; Cytokines; Diltiazem; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Inflammation; Inflammation Mediators; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Microfluidics; Platelet Activation; Protein Kinase Inhibitors; Pyridazines; Thrombosis	2019

Article

Year

Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.

Thrombosis and haemostasis, 2019, Volume: 119, Issue:7

Topics: Animals; Antineoplastic Agents; Blood Platelets; Cells, Cultured; Cytokines; Diltiazem; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Inflammation; Inflammation Mediators; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Microfluidics; Platelet Activation; Protein Kinase Inhibitors; Pyridazines; Thrombosis

2019